BioSpace News Archive

National Resilience, Inc. (Resilience), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem, announced that the Government of Canada will invest CAD 199.2 million ($163.8 million), through the Strategic Innovation Fund , in the company’s Ontario-based subsidiary Resilience Biotechnologies Inc. (RBI) to modernize and expand production capacity.

MYND Life Sciences Inc. a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce that the Company has filed and obtained a receipt for its final non-offering prospectus from the British Columbia Securities Commission.

Dr. Fang has authored 15 published papers including two on axonal transport and several on protein aggregation

The Agreement, entered into May 4, 2021, will see Ofichem provide GMP DMT product as well as the required analytical data package for use in the previously announced phase 1 human clinical trial to be conducted by the Centre for Human Drug Research.

Medical Indicators, Inc., the largest manufacturer of clinically-accurate single-use thermometers in the world, announces the launch of their blog in an effort to educate, inform, and connect with industry partners, medical personnel, and most importantly, the customers they serve.

The Prime Meridian Group is providing Oxford BioDynamics Plc, a biotechnology company focused on the discovery and development of 3D genomic biomarkers for use within the pharmaceutical and biotechnology industry, assistance with market research related to the testing for the award-winning, proprietary technology platform, EpiSwitch™.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 p.m. ET.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2021. First Quarter Financial Highlights: Total revenue for the first quarter of 2021 was $12.2 million, at the high end of the previously provided range of $12.0 million to $12.2 million.

The ALS Association announced a goal of making ALS a livable disease by 2030. Currently, there are no cures or significant life-extending treatments for the fatal neurodegenerative disease.

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair 41st Annual Growth Stock Virtual Conference on Tuesday, June 1, 2021 .